ClearPoint Neuro (CLPT) CFO settles RSUs and withholds shares for taxes

Rhea-AI Filing Summary

ClearPoint Neuro, Inc.’s Chief Financial Officer Danilo D’Alessandro reported routine equity compensation activity involving restricted stock units. On March 11, 2026, 4,145 restricted stock units settled into the same number of common shares at a stated price of $0.00 per share, reflecting non-cash vesting.

In connection with this vesting, 2,109 common shares were delivered back to ClearPoint Neuro at $11.62 per share to satisfy tax withholding obligations, not as an open-market sale. After these transactions, D’Alessandro directly held 86,658 shares of common stock.

Insider Trade Summary

4,145 shares exercised/converted

Mixed 3 txns

Insider D'Alessandro Danilo

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	4,145	$0.00	--
Exercise	Common Stock	4,145	$0.00	--
Tax Withholding	Common Stock	2,109	$11.62	$25K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Common Stock — 88,767 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

D'Alessandro Danilo

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		M		4,145	A	(1)	88,767	D
Common Stock	03/11/2026		F		2,109(2)	D	$11.62	86,658	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/11/2026		M			4,145	(1)	(1)	Common Stock	4,145	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.

	/s/ Danilo D'Alessandro	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ClearPoint Neuro (CLPT) disclose in this Form 4 filing?

ClearPoint Neuro reported its CFO’s equity compensation activity. 4,145 restricted stock units vested into common shares, and a portion of those shares was delivered back to the company to cover tax withholding, leaving him with 86,658 directly held common shares.

How many ClearPoint Neuro shares did the CFO acquire through RSU vesting?

The CFO acquired 4,145 shares of ClearPoint Neuro common stock through settlement of restricted stock units. Each restricted stock unit converted into one share on the scheduled vesting date, as part of his existing equity compensation package with the company.

How many ClearPoint Neuro shares were used for tax withholding in this Form 4?

A total of 2,109 ClearPoint Neuro common shares were delivered back to the company at $11.62 per share. This disposition was solely to satisfy applicable tax withholding obligations arising from the RSU vesting, not an open-market sale transaction by the CFO.

What are the CFO’s ClearPoint Neuro share holdings after these transactions?

Following the RSU vesting and related tax withholding, the CFO directly holds 86,658 shares of ClearPoint Neuro common stock. This figure reflects his updated post-transaction ownership position as reported in the Form 4, with no remaining restricted stock units from this grant.

Was there an open-market sale of ClearPoint Neuro (CLPT) shares by the CFO?

No open-market sale was reported. The only disposition involved 2,109 shares delivered to ClearPoint Neuro at $11.62 per share to cover tax withholding triggered by RSU vesting, which is categorized as a tax-withholding disposition, not a discretionary market sale.